Lymphedema – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Lymphedema is a chronic ailment characterized by the accumulation of lymphatic fluid within the body, resulting in swelling and potential alterations in skin and tissue. This condition emerges due to the persistent buildup of protein-rich fluid in the interstitial spaces and fibro-adipose tissue, surpassing the lymphatic system's ability to transport the fluid effectively. Swelling, a hallmark of lymphedema, can manifest in various body parts, including the arms, legs, face, neck, genitals, chest wall, and oral cavity. The diagnosis of lymphedema brings about a range of psychological, physical, and social consequences. It is classified into two main types: primary lymphedema, which is genetic, and secondary lymphedema, which arises from external causes. Lymphedema's signs and symptoms encompass swelling in the extremities, like the arms, hands, legs, and feet. Additionally, it can lead to swelling in the breast, chest, shoulder, pelvis, groin, face, and intraoral tissues. Movement in joints becomes restricted due to swelling and tissue alterations, and there might be skin discoloration, pain, changed sensation, limb heaviness, and challenges with clothing fitting properly. Primary lymphedema is an inherent or congenital disorder brought about by lymphatic system malformation, often due to genetic mutations. This type can be categorized into three subtypes: congenital lymphedema, apparent from birth or within the initial two years of life; lymphedema praecox, which occurs around puberty or the start of the third decade; and lymphedema tarda, which commences after the age of 35. Secondary lymphedema, on the other hand, emerges due to damage, injury, or blockage of the lymphatic system. The severity of lymphedema is often described through a staging system:
- Stage 0: No observable swelling, but subtle sensations such as a heavy or full feeling in the affected area or tight skin.
- Stage 1 - Swelling in the affected area, with increased size and stiffness. Elevation of the limb tends to alleviate the swelling.
- Stage 2 - Greater swelling compared to stage 1, not improved by elevation. The affected area becomes hard and larger.
- Stage 3 - Significantly more swelling than in stage 2. The extremity might become so swollen that self-movement is impeded. Skin dryness and thickening can lead to fluid leakage or blister formation.
Complications associated with lymphedema encompass recurrent Cellulitis, Lymphangitis, Superficial bacterial and fungal infections, Lymphangio-adenitis, and Deep vein thrombosis (DVT). Post-surgery, complications like Partial wound separation, Seroma, Hematoma, and Skin necrosis are common. Unfortunately, there is no definitive cure for lymphedema. Treatment primarily revolves around diminishing swelling and averting complications. Diligent therapeutic approaches and preventive measures are crucial in mitigating symptoms, slowing or halting disease progression, and preventing further complications. Patients with chronic lymphedema over a decade face a 10% risk of developing lymphangiosarcoma. This aggressive tumor often necessitates extremity amputation and carries a very poor prognosis, with less than 10% five-year survival rate.
- Primary lymphedema is a rarity, impacting just one in every 100,000 individuals. In contrast, secondary lymphedema is the predominant cause of the condition, afflicting around one in every 1,000 Americans.
Thelansis’s “Lymphedema Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Lymphedema treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Lymphedema across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Lymphedema Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment